149 related articles for article (PubMed ID: 29961080)
21. Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy.
Zhang WY; Liu Y; Wang Y; Nie J; Guo YL; Wang CM; Dai HR; Yang QM; Wu ZQ; Han WD
Gene Ther; 2018 Jun; 25(3):198-204. PubMed ID: 29599530
[TBL] [Abstract][Full Text] [Related]
22. Cell and gene therapies at the forefront of innovative medical care: Implications for South Africa.
Pepper MS; Alessandrini M; Pope A; Van Staden W; Green RJ
S Afr Med J; 2018 Dec; 109(1):20-22. PubMed ID: 30606299
[TBL] [Abstract][Full Text] [Related]
23. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
24. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Maude SL
Clin Adv Hematol Oncol; 2018 Oct; 16(10):664-666. PubMed ID: 30543595
[No Abstract] [Full Text] [Related]
25. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
26. Exploring the Potential of CAR-T Therapy for Heart Failure.
Hampton T
JAMA; 2019 Dec; 322(21):2066-2067. PubMed ID: 31794609
[No Abstract] [Full Text] [Related]
27. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Harris DT; Kranz DM
Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
[TBL] [Abstract][Full Text] [Related]
28. Relapses After CAR-T Therapy.
Abbasi J
JAMA; 2018 Nov; 320(18):1850. PubMed ID: 30422179
[No Abstract] [Full Text] [Related]
29. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.
Wang X; Rivière I
Cancer Gene Ther; 2015 Mar; 22(2):85-94. PubMed ID: 25721207
[TBL] [Abstract][Full Text] [Related]
30. New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
Wang J; Zhou P
Adv Exp Med Biol; 2017; 1026():371-381. PubMed ID: 29282693
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
[TBL] [Abstract][Full Text] [Related]
32. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
33. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
34. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
35. Tisagenlecleucel (Kymriah) for ALL.
Med Lett Drugs Ther; 2017 Oct; 59(1532):177-178. PubMed ID: 29039821
[No Abstract] [Full Text] [Related]
36. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
37. CAR T-cell therapy: toxicity and the relevance of preclinical models.
Kalaitsidou M; Kueberuwa G; Schütt A; Gilham DE
Immunotherapy; 2015; 7(5):487-97. PubMed ID: 26065475
[TBL] [Abstract][Full Text] [Related]
38. Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.
Kenderian SS; June CH; Gill S
Methods Mol Biol; 2017; 1633():267-276. PubMed ID: 28735493
[TBL] [Abstract][Full Text] [Related]
39. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
40. Overcoming Challenges in CAR T-cell Product CGMP Release.
Quintarelli C; Locatelli F; Caruana I; De Angelis B
Mol Ther; 2016 May; 24(5):845-6. PubMed ID: 27198849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
